Spectrum Pharmaceuticals (SPPI) Stock Forecast, Price Target & Predictions
SPPI Stock Forecast
Spectrum Pharmaceuticals stock forecast is as follows: an average price target of $0.75 (represents a -27.18% downside from SPPI’s last price of $1.03) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
SPPI Price Target
The average price target for Spectrum Pharmaceuticals (SPPI) is $0.75 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $0.75 to $0.75. This represents a potential -27.18% downside from SPPI's last price of $1.03.
SPPI Analyst Ratings
According to 4 Wall Street analysts, Spectrum Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for SPPI stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 2 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Spectrum Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Feb 03, 2023 | - | Cantor Fitzgerald | $0.75 | $0.81 | -7.41% | -27.18% |
The latest Spectrum Pharmaceuticals stock forecast, released on Feb 03, 2023 by Cantor Fitzgerald company, set a price target of $0.75, which represents a -7.41% decrease from the stock price at the time of the forecast ($0.81), and a -27.18% decrease from SPPI last price ($1.03).
Spectrum Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.03 | $1.03 | $1.03 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Spectrum Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Spectrum Pharmaceuticals's last price of $1.03. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 03, 2023 | Cantor Fitzgerald | Neutral | Neutral | Hold |
| Nov 16, 2022 | B. Riley Securities | - | Neutral | Downgrade |
| Sep 23, 2022 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Sep 12, 2022 | Prescience Point | - | Buy | Upgrade |
Spectrum Pharmaceuticals's last stock rating was published by Cantor Fitzgerald on Feb 03, 2023. The company gave SPPI a "Neutral" rating, the same as its previous rate.
Spectrum Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GMDA | Gamida Cell | $0.03 | $7.00 | 23233.33% | Buy |
| HEPA | Hepion Pharmaceuticals | $0.69 | $70.00 | 10044.93% | Buy |
| BLUE | bluebird bio | $0.31 | $14.13 | 4458.06% | Hold |
| KPTI | Karyopharm Therapeutics | $0.77 | $7.33 | 851.95% | Buy |
| LXRX | Lexicon Pharmaceuticals | $0.88 | $6.00 | 581.82% | Buy |
| IMMP | Immutep | $2.02 | $8.50 | 320.79% | Buy |
| ZURA | Zura Bio | $3.15 | $10.00 | 217.46% | Buy |
| VSTM | Verastem | $3.96 | $8.33 | 110.35% | Buy |
| ARDX | Ardelyx | $4.79 | $8.75 | 82.67% | Buy |
| MCRB | Seres Therapeutics | $0.69 | $1.25 | 81.16% | Buy |
| GERN | Geron | $3.79 | $6.13 | 61.74% | Buy |
| IBRX | ImmunityBio | $5.35 | $8.00 | 49.53% | Buy |
| CRVS | Corvus Pharmaceuticals | $8.40 | $10.67 | 27.02% | Buy |
| AGIO | Agios Pharmaceuticals | $54.41 | $48.00 | -11.78% | Buy |
| SPPI | Spectrum Pharmaceuticals | $1.03 | $0.75 | -27.18% | Buy |
| RIGL | Rigel Pharmaceuticals | $23.91 | $1.50 | -93.73% | Buy |